Prenatal microarray analysis is recommended by the American College of Obstetrics and Gynecology (ACOG) in lieu of karyotyping for all women undergoing prenatal diagnosis, regardless of maternal age.1
Invitae offers two single nucleotide variant (SNV) options for prenatal diagnosis:
Prenatal whole genome microarray offers maximum sensitivity across the genome but has a slightly higher variant of uncertain significance (VUS) rate.
Prenatal targeted microarray looks at a carefully curated selection of the genome in regions with known clinical significance to provide maximum sensitivity and a lower VUS rate.
Identifies microdeletion/microduplication syndromes not detectable through karyotyping
Simultaneously detects maternal cell contamination on direct microarray analysis of amniotic fluid or chorionic villi without the need for a maternal blood sample
Allows for more precise medical management and genetic counseling
Following a normal fetal ultrasound and normal fetal karyotype
1 in 60 women with a normal fetal ultrasound and a normal fetal karyotype have a chromosome abnormality identified by microarray analysis.
Following an abnormal fetal ultrasound and normal fetal karyotype
1 in 17 women with fetal structural anomalies detected by ultrasound and a normal fetal karyotype had a chromosomal abnormality identified by microarray analysis.
Following a negative NIPS result with fetal structural anomalies identified by ultrasound
Diagnostic microarray analysis provides valuable confirmatory information following a negative NIPS result paired with a structural ultrasound abnormality.
Following a positive NIPS result
Diagnostic microarray analysis provides diagnostic confirmation of an abnormality suspected on NIPS, and provides confirmation of a normal result indicating a false positive.
Microarray results are typically available in 7-8 days from the time samples are received by Invitae’s lab.
G-banded karyotype analysis offers detection of numeric chromosome abnormalities, balanced and unbalanced chromosome rearrangements, and polyploidy in 10-12 days on average.
Invitae’s rapid interphase fluorescent in situ hybridization (FISH) does not require a cell sample and looks at a small subset of chromosomes to help you get confirmatory answers when you need them fast. Results are typically available in 24-48 hours, in comparison to metaphase FISH tests which do require a cell sample and typically take 14+ days.
In additional to traditional karyotyping, Invitae offers two single nucleotide polymorphism (SNV) microarray testing options so you can find the right test for every patient—all from one lab.
Invitae technology provides superior, clinically focused, genome-wide coverage.
Invitae provides references to assist in patient counseling and links to tools for evaluating non-copy number related abnormalities, such as regions of homozygosity.
Invitae’s laboratory directors have decades of experience in interpreting microarray results and can assist you in understanding complex results.
Invitae is proud to be in-network with over 250 million patients. We also offer a financial assistance program to uninsured patients.
Request a free specimen collection kit online.
Order a test using a paper test requisition form.
Receive a comprehensive results report
offers healthy adults an opportunity to assess their heritable cancer risk so they can take proactive action if necessary.
uses proven next-generation sequencing technology to provide accurate results with the lowest failure rate.
is recommended by the American College of Obstetricians and Gynecologists for all women of reproductive age, either before or during pregnancy.
can identify the cause of recurrent miscarriage, intrauterine fetal demise, and stillbirth to help inform patients' future reproductive plans.
ACOG Practice Bulletin No. 163 (replaces practice bulletin No. 77, January 2007): Screening for Fetal Aneuploidy. Practice Bulletin No. 163. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2016;127(5):e123-37.